Results 71 to 80 of about 34,994 (236)

INCB054828 inhibits FGFR-dependent signaling pathways.

, 2020
(A) KG1a or (B) RT-4 cells were treated with INCB054828 for 2 hours, lysed and subjected to immunoblotting for phospho- and total proteins in the FGFR signal transduction pathway including FGFR, ERK, FRS2, and STAT5.
Kevin Bowman (5435744), Wenqing Yao (314606), Xiaoming Wen (1302228), Mark Rupar (2537560), Patricia Feldman (7541663), Yue Zhang (30585), Timothy C. Burn (2332189), Maryanne Covington (2139592), Gregory Hollis (2245555), Krista A. Burke (8741697), Peggy Scherle (2139556), Christine Gardiner (8741703), Richard Wynn (2332183), Reid Huber (2666968), Liangxing Wu (418408), Swamy Yeleswaram (2139574), Sharon Diamond (2139568), Michael Hansbury (8741694), Holly Koblish (5435765), Ronald Klabe (2666971), Maxim Soloviev (8741700), Paul Collier (2069650), Phillip C. C. Liu (8741688), Darlise DiMatteo (8741691), Xin He (48101), Bruce Ruggeri (2080048), Alla Volgina (8741706)   +26 more
core   +1 more source

Clinical advances and challenges in targeting FGF/FGFR signaling in lung cancer

Molecular Cancer
Fibroblast growth factors (FGFs) and their receptors regulate numerous cellular processes, such as metabolism and signal transduction, but can also drive tumorigenesis.
Mei Peng, Jun Deng, Xiangping Li
doaj   +1 more source

FGFR families: biological functions and therapeutic interventions in tumors

MedComm, 2023
There are five fibroblast growth factor receptors (FGFRs), namely, FGFR1–FGFR5. When FGFR binds to its ligand, namely, fibroblast growth factor (FGF), it dimerizes and autophosphorylates, thereby activating several key downstream pathways that play an ...
Qing Liu, Jiyu Huang, Weiwei Yan, Zhen Liu, Shu Liu, Weiyi Fang   +5 more
doaj   +1 more source

The binding of NCAM to FGFR1 induces a specific cellular response mediated by receptor trafficking [PDF]

, 2009
Neural cell adhesion molecule (NCAM) associates with fibroblast growth factor (FGF) receptor-1 (FGFR1). However, the biological significance of this interaction remains largely elusive.
Vladimir Berezin, Gerhard Christofori, Christofori, Gerhard, Francavilla, Chiara; id_orcid, Paola Cattaneo, Cattaneo, Paola, Ugo Cavallaro, Cavallaro, Ugo, de Marco, Ario, Francavilla, Chiara, Ami, Diletta, Berezin, Vladimir, Ario de Marco, Chiara Francavilla, Bock, Elisabeth, Elisabeth Bock, Diletta Ami   +16 more
core   +1 more source

Altered Fibroblast Growth Factor Receptor 4 Stability Promotes Prostate Cancer Progression

Neoplasia: An International Journal for Oncology Research, 2008
Fibroblast growth factor receptor 4 (FGFR-4) is expressed at significant levels in almost all human prostate cancers, and expression of its ligands is ubiquitous.
Jianghua Wang, Wendong Yu, Yi Cai, Chengxi Ren, Michael M. Ittmann   +4 more
doaj   +1 more source

Prospective multicenter study of ctDNA versus tumor tissue guiding FGFR-targeted therapy in metastatic urothelial cancer

Nature Communications
Fibroblast growth factor receptor (FGFR) alterations are targetable in metastatic urothelial carcinoma (mUC). Identifying FGFR alterations currently requires tissue testing, which is limited by sample availability and cancer heterogeneity.
David C. Müller, Andrew J. Murtha, Jack V. W. Bacon, Maria Stephenson, Connor Wells, Carlos Vasquez-Rios, Kimia Rostin, Lisa Rebane, Elena Schönlau, Jussi Nikkola, Nimira Alimohamed, Naveen S. Basappa, Daygen Finch, Jenny J. Ko, Jean-Michel Lavoie, Lucia Nappi, Krista Noonan, Michael Ong, Guliz Ozgun, Sunil Parimi, Maryam Soleimani, Srikala S. Sridhar, Paul Toren, Eric Winquist, Cecily Q. Bernales, Melissa Koudjanian, Jaskirat Atwal, Emily Fung, Laiba Khan, Bryndan Eigl, Dalia Othman, Tarek A. Bismar, Gang Wang, Reem Merza, Andreas I. Papadakis, Alan Spatz, Christian Kollmannsberger, Corinne Maurice-Dror, Matti Annala, Kim N. Chi, Gillian Vandekerkhove, Alexander W. Wyatt, Bernhard J. Eigl   +42 more
doaj   +1 more source

Immunohistochemical expression of FGF-2, FGFR-2 and FGFR-3 in OSCC and PMOLs.

, 2015
Immunohistochemical expression of FGF-2, FGFR-2 and FGFR-3 in OSCC and PMOLs.
Vikram Bhatia (406012), Seema Nayak (813016), Annu Makker (813017), Saumya Chandra (813018), Sandeep Kumar (145759), Madhu Mati Goel (473426), S. P. Agarwal (813019)   +6 more
core   +1 more source

Clinical Implementation and Oncological Relevance of Molecular Profiling in Brain Metastases Patients—A Multicenter Retrospective Cohort Study

International Journal of Cancer, EarlyView.
While current guidelines recommend the analysis of established cancer driver genes in brain metastases, little is known about its real‐life implementation. This multicenter study revealed an upward trend in the profiling rates of surgically treated brain metastases over the past decade, with up to 60% of brain metastases samples undergoing analysis ...
Maria Nikolaeva, Jacopo Bellomo, Meltem Gönel, Vittorio Stumpo, Victor Egon Staartjes, Flavio Vasella, Kevin Akeret, André Sagerer, Anna Maria Zeitlberger, David Wasilewski, Christopher Krämer, Sven König, Julia Onken, Tareq Juratli, Alexander Köpp, Regina Reimann, Marcus Czabanka, Peter Vajkoczy, Ilker Y. Eyüpoglu, Oliver Bozinov, Michael Weller, Emilie Le Rhun, Luca Regli, Carlo Serra, Marian C. Neidert, Stefanos Voglis   +25 more
wiley   +1 more source

Adjuvant Chemotherapy Regimens in Resected Biliary Tract Cancers: National, Comparative, Observational Study (TOG/GI‐SAFRADJU‐2501)

International Journal of Cancer, EarlyView.
ABSTRACT The recommended adjuvant chemotherapy (adj‐ChT) regimen for resected biliary tract cancers (BTC) is capecitabine (Cape); yet, the recommendation is based on limited evidence. Although varied adj‐ChTs have been employed in practice, robust real‐world data is scarce. We conducted a national, multicenter, hospital‐based registry study to evaluate
Erman Akkus, Mehmet Kayaalp, Müzeyyen Aslı Ergözoğlu, Ilgın Koç Kuş, Doğan Bayram, Bilgeşah Kılıçtaş, Emel Ayvaz Güneyin, Ali Kalem, Haydar Temizyürek, Mehmet Mutlu Çatlı, Mehmet Sinan Akarca, Maral Martin Mıldanoğlu, Görkem Turhan, Mahmut Kara, Hacı Arak, Feyza Arslan Tan, Burak Paçacı, Berkay Yeşilyurt, Orhun Akdoğan, Emine Bihter Çetin, Selahattin Çelik, Fatma Keskin Uzundere, Elif Şahin, Zehra Sadak Öcal, Lamia Şeker Can, Bahadır Köylü, Mehmet Cem Fidan, Esmanur Kaplan Tüzün, Teoman Şakalar, Elif Sertesen Çamöz, Haydar Çağatay Yüksel, Onur Yazdan Balçık, Pınar Peker, Mehmet Yılmaz, Şeymanur Ala Enli, Erdem Kölemen, Sibel Oyucu Orhan, Yakup Düzköprü, Mustafa Ersoy, Tuğba Akın Telli, Mesut Yılmaz, Yusuf İlhan, Atila Yıldırım, Ramazan Coşar, Müslih Ürün, Arif Hakan Önder, Murat Araz, Ertuğrul Bayram, Havva Yeşil Çınkır, Ali Alkan, Mustafa Gürbüz, Nilüfer Avcı, Fatma Paksoy Türköz, İsmail Oğuz Kara, Fatih Köse, İlkay Tuğba Ünek, Ahmet Bilici, Öznur Bal, Şuayib Yalçın, Lorenza Rimassa, Hatime Arzu Yaşar   +60 more
wiley   +1 more source

Immunohistochemical staining of FGFR-2 (A-C).

, 2015
A, FGFR-2 positivity in transformed cases of Leukoplakia with dysplasia X 200. B, FGFR-2 positivity in transformed case of OSMF in fibrosis area X 100. C, FGFR-2 positivity in OSCC X 100.
Vikram Bhatia (406012), Seema Nayak (813016), Annu Makker (813017), Saumya Chandra (813018), Sandeep Kumar (145759), Madhu Mati Goel (473426), S. P. Agarwal (813019)   +6 more
core   +1 more source